1. Progression-free survival was significantly greater in the lenvatinib plus pembrolizumab group compared to placebo. 2. Overall survival was higher ...
1. Pembrolizumab plus radiotherapy and surgery significantly improved disease-free survival. 2. Grade 3 or higher adverse events were more common ...
1. In this randomized controlled trial, among patients with early-stage triple-negative breast cancer (TNBC), the addition of neoadjuvant and adjuvant ...
1. 36-month overall survival and median event-free survival were significantly greater in the pembrolizumab group compared to control. 2. Grade ...
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly ...
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with ...
1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly ...
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with ...
